EZZ Life Sciences secures $10 million global distribution deal with Aumake
EZZ Life Sciences (ASX: EZZ) has entered a four-year EZZ Life Sciences Distribution Agreement with Aumake Limited (ASX: AUK), establishing exclusive global distribution rights targeting minimum sales of $10 million. The agreement covers three core products: EZZ Glutathione Health Support, EZZ Vitality Boost, and EZZ Sleep, with provisions to expand the product range through co-development targeting China market demand.
The arrangement grants Aumake exclusive global distribution rights across all channels, backed by minimum purchase commitments of $2.5 million per contract year over the four-year term. This structure provides EZZ with predictable wholesale revenue whilst leveraging Aumake’s established sales infrastructure across B2C e-commerce platforms and B2B distribution networks. The agreement includes scope to develop additional products tailored to China market preferences.
For investors, this locked-in revenue pathway reduces execution risk by outsourcing distribution to a partner with proven sales capability in the target geography. EZZ retains full ownership of intellectual property and branding whilst offloading the operational complexity of direct market penetration.
Understanding exclusive distribution agreements in the nutraceutical sector
An exclusive distribution agreement grants one partner sole rights to sell specified products within defined territories and channels. In the nutraceutical sector, this model allows manufacturers to access established distribution networks without building their own sales infrastructure, reducing marketing overhead and accelerating market entry.
The structure differs materially from non-exclusive arrangements where multiple distributors compete for the same customer base. Exclusive agreements typically include minimum purchase commitments that align incentives, as distributors have guaranteed territory protection whilst manufacturers secure baseline revenue. The partner assumes inventory risk and customer relationship management whilst the manufacturer retains brand control.
This arrangement matters to investors because it converts uncertain future revenue into contractually committed minimums. EZZ maintains intellectual property ownership and brand oversight whilst transferring distribution execution risk to Aumake, which has existing sales channels in the target markets.
Agreement structure and key commercial terms
The EZZ Life Sciences Distribution Agreement establishes clear performance accountability mechanisms. Failure to meet either the aggregate $10 million sales requirement or the annual $2.5 million minimum results in automatic termination of worldwide exclusive rights. This clause protects EZZ from underperforming partnerships whilst incentivising Aumake to exceed minimum targets.
The commercial framework includes a cooperative manufacturing model designed to ensure healthy margins for both parties. Sales and marketing execution occurs through Aumake’s proven B2C e-commerce platforms and B2B distribution network, with Aumake handling customer acquisition and order fulfilment.
| Term | Detail |
|---|---|
| Territory | Global |
| Exclusivity | Exclusive across all channels |
| Duration | 4 years |
| Total Minimum | A$10 million |
| Annual Minimum | A$2.5 million |
EZZ retains full ownership of intellectual property and branding throughout the agreement term. This preserves strategic optionality for the company to pursue alternative distribution channels or partnerships in future if performance warrants it.
Aumake’s distribution track record
Aumake brings demonstrated capability in the exact product category covered by the agreement. The distributor has recorded more than $2.1 million in nutraceutical sales since 2025, split between $1.6 million in wholesale B2B channels and $0.5 million in B2C direct sales. Nutraceuticals represent Aumake’s highest-margin product segment within its nutritionals channel.
The partner operates across multiple sales channels:
- B2C e-commerce platforms targeting Chinese consumers
- B2B distribution network servicing retail partners
- Focus on China market demand, aligned with product development provisions in the agreement
This existing sales infrastructure means EZZ gains immediate access to established customer relationships and operational capability rather than partnering with an unproven distributor. The partner selection is evidence-based, with Aumake having already demonstrated sales volume in the target market and product category.
Strategic context and growth pathway
The EZZ Life Sciences Distribution Agreement forms part of EZZ’s broader omnichannel distribution strategy across Australia, New Zealand, China, and global markets. The agreement structure includes provisions for co-developing new products tailored to China market demand, creating optionality beyond the initial three-product range.
Aumake Chairman Dr Anthony Noble emphasised the strategic alignment between the partners, noting that successful execution could serve as proof of concept for additional brand collaborations:
Aumake Chairman Dr Anthony Noble
“This expansion of our partnership with EZZ, which is highly aligned with our core strategy, comes on the back of a strong focus on compliance and the tighter commercial business processes that have been put in place in 2026, without which this deal would not have been possible. We believe this will be the first of many future collaborations that are now beginning to open to a refreshed and rejuvenated company. Successfully completing and executing this distribution partnership with EZZ and, we hope, far surpassing the minimum value in the contract, will serve as a proof point for other brands to collaborate with us in the Chinese e-commerce and B2B / retail distribution markets.”
Dr Noble referenced Aumake’s pending rebrand to Xenitra (ASX: XEN), reflecting broader ambitions in terms of products, markets, and value generation. The EZZ product range is positioned to benefit from the expanded Xenitra platform offering during 2026.
For investors, the agreement creates optionality that extends beyond the stated $10 million minimum. Success could unlock expanded product ranges developed specifically for high-demand categories in China, whilst serving as a template for future distribution partnerships with other brands. This amplifies the revenue opportunity if execution meets or exceeds targets.
What investors should watch
- Quarterly sales updates against the $2.5 million annual minimum, which will indicate whether the partnership is tracking to baseline or exceeding targets.
- Announcements of additional products added to the distribution scope, particularly co-developed formulations targeting China market preferences.
- Co-developed product launches that extend beyond the initial three-product range, signalling expanded partnership scope.
- Updates on Aumake’s rebranding to Xenitra (ASX: XEN) and any platform expansion announcements that could benefit EZZ product distribution.
Want the Next Consumer Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to receive alerts the moment market-moving announcements drop across Consumer, Tech, Healthcare, Finance, and more.